Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: PP-MI health behavior intervention;   Behavioral: Diabetes education intervention
Sponsor:   Massachusetts General Hospital
Not yet recruiting - verified May 2017

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient

Condition:   Renal Insufficiency,Type 2 Diabetes
Intervention:   Drug: SHR3824
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified June 2016

Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified May 2017

Adipose Tissue Expadability and Type 2 Diabetes

Condition:   Type2 Diabetes Mellitus
Intervention:  
Sponsor:   Charles University, Czech Republic
Recruiting - verified July 2016

Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SHR3824;   Drug: Placebo
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting - verified May 2017

Efficacy of an Electronic System to Support Clinical Decisions in Adults With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: Clinical Decision Support System;   Other: Usual care based on clinical practice guideline
Sponsor:   Sanitas University
Not yet recruiting - verified May 2017

Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus

Condition:   Diabetes
Intervention:   Other: Meal replacement
Sponsor:   Nestlé
Recruiting - verified May 2017

Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.

Condition:   Evaluation Thyroid Functions in Diabetic Patient
Intervention:  
Sponsor:   Assiut University
Enrolling by invitation - verified May 2017

PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy

Condition:   T2DM (Type 2 Diabetes Mellitus)
Intervention:   Drug: Metformin
Sponsor:   People's Hospital of Zhengzhou University
Completed - verified May 2017

Effect of Acute Fructose Load in Human

Conditions:   Chronic Kidney Diseases;   Diabetes Mellitus, Type 2
Interventions:   Other: Blueberry drink;   Other: Blueberry and pizza;   Other: Soft beverage;   Other: Soft beverage and pizza;   Other: Fructose;   Other: Fructose and pizza
Sponsor:   Karolinska University Hospital
Recruiting - verified May 2017

A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes

Condition:   Type2 Diabetes
Interventions:   Behavioral: PP-MI health behavior intervention;   Behavioral: MI-based health behavior education intervention
Sponsor:   Massachusetts General Hospital
Not yet recruiting - verified May 2017

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Condition:   Diabetes Type 2 With Heart Failure
Interventions:   Drug: LIK066;   Drug: Placebo;   Drug: Empagliflozin
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified May 2017

Prediction of Fetal Lung Maturity

Condition:   Fetal Distress
Interventions:   Radiation: fetal lung volume;   Radiation: pulmonary artery resistance index;   Radiation: Fetal adrenal gland volume:
Sponsor:   Assiut University
Completed - verified May 2017

An Egg Based Breakfast Maintains Flexibility in Older Adults

Conditions:   Diabetes;   Heart Diseases
Interventions:   Other: High fat breakfast;   Other: Higher carbohydrate breakfast
Sponsor:   University of Alabama at Birmingham
Completed - verified May 2017

The Early Predictors for Developing Type 2 Diabetes Mellitus in Patients With Chronic Obstructive Pulmonary Disease

Conditions:   Chronic Obstructive Pulmonary Disease;   Type 2 Diabetes Mellitus
Intervention:   Other: Checking fasting blood glucose(FBG)
Sponsor:   Zhujiang Hospital
Recruiting - verified April 2017

Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Yo Puedo + mHealth
Sponsors:   Yale University;   Universidad Iberoamericana
Recruiting - verified May 2017

Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Arrhythmia, Cardiac
Interventions:   Other: Combined hyper- and hypoglycaemic clamp;   Device: Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA);   Device: Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)
Sponsor:   University Hospital, Gentofte, Copenhagen
Enrolling by invitation - verified May 2017

High-intensity Training, Self-monitoring and Diabetes 2

Conditions:   Diabetes Mellitus;   High-Intensity Interval Training;   Self Care
Intervention:   Other: High-Intensity Training
Sponsors:   University College of Northern Denmark;   Aalborg University
Completed - verified May 2017

A Study of LY3298176 in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY3298176;   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified May 2017

Increased Protein at Breakfast for Weight Management in Overweight Adolescents

Condition:   Obesity, Adolescent
Intervention:   Behavioral: Breakfast
Sponsors:   Purdue University;   University of Kansas Medical Center;   University of Tennessee;   Banner Alzheimer's Institute
Not yet recruiting - verified May 2017

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Conditions:   Diabetes Mellitus, Type 2;   Kidney Function Tests
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Not yet recruiting - verified May 2017

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: metformin;   Drug: ipragliflozin;   Drug: glimepride
Sponsor:   Astellas Pharma Korea, Inc.
Recruiting - verified May 2017

Hypoglycemic Efficacy of Greenyn Momordica Charantia Extracts in Diabetic Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Dietary Supplement: Greenyn Momordica charantia extracts;   Dietary Supplement: Placebo control
Sponsor:   Chung Shan Medical University
Recruiting - verified May 2017

Acute Effect of Axulin on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans

Condition:   Insulin Resistance, Diabetes
Interventions:   Other: Placebo capsules;   Other: 2g Axulin capsules;   Other: 4g Axulin capsules;   Other: 0g Axulin tablets;   Other: 2g Axulin tablets;   Other: 4g Axulin tablets
Sponsors:   Glycemic Index Laboratories, Inc;   Housey Healthcare, ULC
Recruiting - verified April 2017

Evaluation of Type 2 Diabetes Treatment

Condition:   Type2 Diabetes
Intervention:   Drug: Diabeton 60 MR
Sponsor:   Servier
Active, not recruiting - verified April 2017

Microbiome Insulin Sensitivity Study

Conditions:   Obesity;   Insulin Resistance;   Type2 Diabetes
Intervention:  
Sponsors:   University of Colorado, Denver;   National Institutes of Health (NIH);   Children's Hospital Colorado
Not yet recruiting - verified May 2017

CGM to Aid Transition From Inpatient to Outpatient

Condition:   Diabete Mellitus
Intervention:   Device: Freestyle Libre
Sponsor:   Methodist Medical Center of Illinois
Active, not recruiting - verified May 2017

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY3325656;   Drug: Placebo;   Drug: Liraglutide;   Drug: Sitagliptin
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified May 2017

STOP DIABETES - Knowledge-based Solutions

Conditions:   Type2 Diabetes;   Life Style;   Diet Habit;   Physical Activity;   Empowerment
Interventions:   Behavioral: Digital lifestyle intervention group;   Behavioral: Combined digital and face-to-face lifestyle intervention group
Sponsors:   University of Eastern Finland;   National Institute of Health and Welfare;   Technical Research Centre of Finland;   University of Melbourne;   University of Konstanz;   Karolinska Institutet;   Maastricht University;   University of Oslo;   Danube-University;   Flinders University;   Cornell University;   University of Copenhagen;   Roskilde University;   University of Manchester;   University of York
Recruiting - verified May 2017

Developing a Positive Psychology Intervention to Improve Health Behaviors in Type 2 Diabetes: Qualitative Research

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Massachusetts General Hospital
Completed - verified May 2017

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Condition:   Type 2 Diabetes Mellitus
Intervention:   Other: Use of digital disease management tool
Sponsor:   AstraZeneca
Recruiting - verified May 2017

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified May 2017

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Canagliflozin;   Drug: Canagliflozin placebo;   Drug: Semaglutide placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec;   Drug: Insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Empagliflozin;   Drug: Placebo Oral Tablet
Sponsors:   Caroline M Kistorp;   Danish Heart Foundation;   Herlev and Gentofte Hospital;   Rigshospitalet, Denmark
Recruiting - verified May 2017

The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Mobile health system;   Other: E-mail reports and technical support for mHealth system
Sponsors:   University of Michigan;   Mahidol University;   John E. Fogarty International Center (FIC)
Not yet recruiting - verified May 2017

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Empagliflozin 10 mg;   Drug: Placebo Oral Tablet
Sponsors:   Medical University of Graz;   United Arab Emirates University;   Medical University of Vienna;   Landeskrankenhaus Feldkirch;   Krankenhaus der Barmherzigen Brüder Linz;   Kepler University Hospital;   Paracelsus Medical University
Recruiting - verified May 2017

Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: placebo;   Drug: Metformin;   Drug: Sulfonylurea
Sponsor:   Sanofi
Recruiting - verified May 2017

A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB

Condition:   Obesity
Interventions:   Procedure: Roux-en-Y gastric bypass surgery;   Behavioral: Very low-calorie diet
Sponsors:   Washington University School of Medicine;   National Center for Advancing Translational Science (NCATS)
Recruiting - verified May 2017

Commercial Prebiotic Supplement Study

Condition:   Diabetes Mellitus, Type 2
Intervention:   Dietary Supplement: 20 ml of prebiotic per day
Sponsor:   University of Aberdeen
Recruiting - verified February 2017

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: Empagliflozin (oral);   Drug: Glimepiride (oral)
Sponsor:   Intarcia Therapeutics
Recruiting - verified May 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Glargine U300 Hospital Trial

Condition:   Type 2 Diabetes
Interventions:   Drug: Glargine U300;   Drug: Glargine U100;   Drug: Glulisine Insulin
Sponsor:   Emory University
Not yet recruiting - verified May 2017

XIGDUO Extended Release (XR) Post Marketing Surveillance

Condition:   Adult Patients With Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2017

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified May 2017

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified May 2017

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Drug: Metformin and Liraglutide
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 12, 2017

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Conditions:   Metabolism and Nutrition Disorder;   Obesity
Interventions:   Drug: Liraglutide 3.0 mg;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: metformin;   Drug: sulfonylurea;   Drug: meglitinides;   Drug: thiazolidinediones;   Drug: alpha-glucosidase inhibitors;   Drug: GLP1 Receptor Agonist;   Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors;   Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors
Sponsor:   Sanofi
Recruiting - verified May 2017

Diabetes Engagement and Activation Platform

Condition:   Type 2 Diabetes (T2D)
Intervention:   Other: Usual Care
Sponsor:   Virginia Commonwealth University
Not yet recruiting - verified May 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified May 2017

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Conditions:   Type 2 Diabetes Mellitus;   Heart Failure
Interventions:   Drug: Saxagliptin;   Drug: Sitagliptin;   Drug: Placebo to match saxagliptin;   Drug: Placebo to match sitagliptin
Sponsor:   AstraZeneca
Recruiting - verified May 2017

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Condition:   Male Subjects With Type II Diabetes (T2DM)
Interventions:   Drug: AZD8601+Placebo (SAD);   Drug: AZD8601+Placebo;   Drug: Placebo+Placebo
Sponsors:   AstraZeneca;   Parexel;   Spandauer Damm 130;   14050;   Berlin, Germany
Recruiting - verified May 2017

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified May 2017

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified May 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2017

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Condition:   Obesity, Visceral
Interventions:   Drug: [U-13C3] glycerol;   Drug: Empagliflozin;   Drug: Placebo (for Empagliflozin)
Sponsors:   University of Texas Southwestern Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2017

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

Condition:   Diabetes Type 2
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Herlev Hospital
Active, not recruiting - verified May 2017

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2017

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin IR
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2017

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified May 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified May 2017

An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Trelagliptin;   Drug: Alogliptin
Sponsor:   Takeda
Completed - verified May 2017

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/insulin aspart;   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified May 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified May 2017

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified May 2017

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2017

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulfonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin L-proline;   Drug: Metformin;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Active, not recruiting - verified May 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017

The Effectiveness of Diabetes Self-Management Education Program Based on Behavioural Change Theory

Conditions:   Health Behavior;   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Diabetes Self-Management Education
Sponsor:   University of Nottingham
Completed - verified May 2017

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Condition:   Non Alcoholic Fatty Liver Disease
Intervention:   Drug: Empagliflozin
Sponsor:   Medanta, The Medicity, India
Completed - verified May 2017

Renoprotective Effects of Dapagliflozin in Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathies
Interventions:   Drug: Dapagliflozin 10mg QD;   Drug: Gliclazide 30mg QD
Sponsors:   M.H.H. Kramer;   AstraZeneca
Recruiting - verified May 2017

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lyophilized albiglutide DCC pen injector;   Drug: Lyophilized albiglutide DCC pen injector matching placebo;   Drug: Albiglutide liquid auto-injector;   Drug: Albiglutide liquid auto-injector matching placebo
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified May 2017

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified May 2017

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Condition:   Dyslipidemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: statins;   Drug: ezetimibe;   Drug: fenofibrate;   Drug: nicotinic acid;   Drug: omega-3 fatty acids
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified May 2017

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
Sponsor:   Intarcia Therapeutics
Active, not recruiting - verified May 2017

A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics

Condition:   Type 1 Diabetes
Intervention:   Device: Harmony 1 Sensor
Sponsor:   Medtronic Diabetes
Not yet recruiting - verified May 2017

Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo

Condition:   Hyperglycaemia
Interventions:   Other: Control without pomegranate juice;   Other: Test with pomegranate juice
Sponsor:   University of Leeds
Completed - verified May 2017

A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Standard of Care
Sponsors:   AstraZeneca;   Quintiles, Inc.;   Clinical Practice Research Datalink
Recruiting - verified May 2017

Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics

Conditions:   Silent Myocardial Ischemia;   Type 2 Diabetes
Interventions:   Drug: Ranolazine;   Drug: Placebo
Sponsor:   Walter Reed National Military Medical Center
Withdrawn - verified May 2017

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified May 2017

NEPHSTROM for Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Biological: Mesenchymal Stromal Cells;   Other: Placebo
Sponsors:   Mario Negri Institute for Pharmacological Research;   Leiden University Medical Center;   ASST Papa Giovanni XXIII, Bergamo, Italy;   IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy;   Belfast Health and Social Care Trust;   National University of Ireland, Galway, Ireland;   University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK;   NHS Blood and Transplant
Not yet recruiting - verified May 2017

Behavioral Family Systems Therapy (BFST) for Teens With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Childhood Obesity
Intervention:   Behavioral: BFST for Teens with Type 2 Diabetes
Sponsor:   Nemours Children's Clinic
Completed - verified May 2017

Continuation of Metformin to Improve And Keep Peri-operative Glycemic Control

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsor:   McMaster University
Not yet recruiting - verified May 2017

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified May 2017

Improving Chronic Disease Management With Pieces

Conditions:   Chronic Kidney Disease;   Diabetes;   Hypertension;   High BP;   Type 2 Diabetes
Intervention:   Other: Collaborative Model of Primary care and Subspecialty care
Sponsors:   University of Texas Southwestern Medical Center;   Parkland Center for Clinical Innovation;   Parkland Health & Hospital System;   Texas Health Resources;   Connecticut Center for Primary Care;   Dallas VA Research Corporation;   G-Health Enterprises
Recruiting - verified May 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified May 2017

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2017

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Completed - verified May 2017

Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)

Conditions:   Prediabetic State;   Metabolic Syndrome X;   Insulin Resistance
Interventions:   Behavioral: Vida Sana;   Other: Usual Care Only
Sponsors:   Palo Alto Medical Foundation;   Agency for Healthcare Research and Quality (AHRQ);   University of Illinois at Chicago;   University of Pittsburgh;   RTI International;   University of California at Santa Cruz
Active, not recruiting - verified May 2017

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified May 2017

A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: Harmony 1 Sensor
Sponsor:   Medtronic Diabetes
Not yet recruiting - verified May 2017

Diabetes Group Prenatal Care

Conditions:   Pregnancy;   Gestational Diabetes;   Type 2 Diabetes
Intervention:   Behavioral: Group prenatal care
Sponsors:   Washington University School of Medicine;   Denver Health Medical Center
Recruiting - verified May 2017

Short Term Intermittent Fasting and Insulin Resistance

Conditions:   Diabetes Mellitus;   Non-alcoholic Fatty Liver Disease;   Metabolic Syndrome;   Obesity
Interventions:   Behavioral: Intermittent fasting;   Other: Time control
Sponsors:   University of Copenhagen;   Herlev Hospital
Active, not recruiting - verified May 2017

Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: REACH;   Behavioral: Helpline and A1c results;   Behavioral: REACH + FAMS
Sponsors:   Vanderbilt University Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2017

Microvascular Dysfunction and the Development of Whole-body Insulin Resistance

Conditions:   Insulin Resistance;   Type 2 Diabetes;   Obesity
Interventions:   Dietary Supplement: Hypercaloric diet;   Other: Normocaloric diet
Sponsors:   VU University Medical Center;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified May 2017

Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes

Condition:   Diabetes Mellitus
Intervention:   Device: Continuous Glucose Monitor
Sponsors:   DexCom, Inc.;   Jaeb Center for Health Research
Completed - verified February 2017

Metabolic Activation With Protein-rich Formula Diet

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: stringent diet regimen;   Dietary Supplement: moderate diet regimen
Sponsors:   West German Center of Diabetes and Health;   Almased Wellness GmbH
Recruiting - verified May 2017

The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease

Condition:   End-stage Renal Disease
Interventions:   Other: Eu- and hyperglycemic clamp;   Other: Arginine test
Sponsor:   Bo Feldt-Rasmussen
Completed - verified May 2017

Continuous Glucose Monitoring in Controls With and Without Cystic Fibrosis

Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   University of Colorado, Denver
Recruiting - verified May 2017

To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery

Conditions:   Bypass, Gastric;   Roux-en-Y Gastric Bypass;   Vertical Sleeve Gastrectomy;   Gastric Banding;   Bariatric Surgery
Interventions:   Drug: Placebo;   Drug: Lo-Xenin;   Drug: Hi-Xenin;   Drug: Extra Hi-Xenin
Sponsors:   Washington University School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified May 2017

Redox Imbalance and the Development of Cystic Fibrosis Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Cystic Fibrosis
Interventions:   Drug: Oral Glucose Tolerance Test;   Other: High Glycemic Index Meal;   Other: Low Glycemic Index Meal
Sponsors:   Emory University;   Cystic Fibrosis Foundation Therapeutics
Recruiting - verified May 2017

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2017

Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   NIDDM;   Non-insulin Dependent Diabetes Mellitus
Intervention:   Behavioral: Home Visits and Lifestyle Education Support
Sponsors:   McMaster University;   Ontario Ministry of Health and Long Term Care;   Canadian Institutes of Health Research (CIHR)
Completed - verified May 2017

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: KAD-1229;   Drug: Placebo;   Drug: Insulin
Sponsor:   Kissei Pharmaceutical Co., Ltd.
Completed - verified May 2017

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Atherosclerosis
Intervention:   Drug: Darapladib
Sponsor:   GlaxoSmithKline
Completed - verified May 2017

Aldosterone, Microvascular Function and Salt-sensitivity

Conditions:   Abdominal Obesity;   Metabolic Syndrome;   Sodium-sensitivity;   Insulin Resistance;   Hypertension
Interventions:   Dietary Supplement: Low-sodium diet;   Dietary Supplement: High-sodium diet
Sponsor:   Maastricht University Medical Center
Completed - verified May 2017

Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria

Condition:   Diabetic Nephropathy
Interventions:   Drug: colchicine 0.5mg/d;   Drug: placebo 0.5mg/d
Sponsor:   Chongqing Medical University
Active, not recruiting - verified May 2017

User Evaluation of the MiniMed 640G Insulin Pump

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Sponsor:   Medtronic Diabetes
Completed - verified March 2016

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 21, 2017

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Completed - verified May 2017

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Condition:   Surveillance
Intervention:   Drug: Alogliptin
Sponsor:   Takeda
Completed - verified May 2017

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

Condition:   Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions:   Drug: Graded Glucose Infusion with Placebo;   Drug: Graded Glucose Infusion with GIP Alone;   Drug: Graded Glucose Infusion with xenin-25 alone;   Drug: Graded Glucose Infusion with GIP plus xenin-25;   Drug: Meal Tolerance Test with Placebo;   Drug: Meal Tolerance Test with xenin-25
Sponsors:   Washington University School of Medicine;   American Diabetes Association
Active, not recruiting - verified May 2017

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

Condition:   Pre-diabetes
Interventions:   Drug: Control;   Drug: Xenin-25 without atropine;   Drug: GIP without atropine;   Drug: Placebo with atropine;   Drug: Xenin-25 with atropine;   Drug: GIP with atropine;   Drug: GIP plus Xenin-25 without atropine;   Drug: GIP plus Xenin-25 with atropine
Sponsors:   Washington University School of Medicine;   American Diabetes Association
Active, not recruiting - verified May 2017

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2017

Aldosterone Antagonism and Microvascular Function

Conditions:   Abdominal Obesity Metabolic Syndrome;   Insulin Resistance;   Hypertension
Interventions:   Drug: Eplerenone;   Other: Placebo
Sponsor:   Maastricht University Medical Center
Recruiting - verified May 2017

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

Condition:   Obesity
Intervention:   Drug: Roflumilast
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 16, 2017

Assessment of an Intervention to Prevent Obesity and Diabetes in Latino Farm Workers

Condition:   Overweight and Obesity
Intervention:   Behavioral: Behavioral Intervention
Sponsor:   University of California, Davis
Completed - verified May 2017

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster-acting insulin aspart;   Drug: Insulin aspart;   Drug: Insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified May 2017

Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix

Conditions:   Obesity;   Diet Therapy;   Diabetes Type 2
Intervention:   Behavioral: Controlling Gestational Weight Gain
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 27, 2017

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Condition:   Type 2 Diabetes
Intervention:   Drug: ITCA 650 (exenatide in DUROS)
Sponsor:   Intarcia Therapeutics
Active, not recruiting - verified May 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2017

iStart Smart for Teens for Healthy Weight Management

Conditions:   Overweight;   Obese
Interventions:   Device: fitbit Ultra;   Device: Pedometer
Sponsor:   University of California, San Francisco
Completed - verified May 2017

Biomarkers of Diabetic Retinopathy Progression

Conditions:   Type 2 Diabetes Mellitus;   Mild Nonproliferative Diabetic Retinopathy
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting - verified May 2017

REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes

Condition:   Type 2 Diabetes
Intervention:   Other: Treatment Algorithms
Sponsors:   University of Pittsburgh;   American Diabetes Association
Completed - verified May 2017

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified May 2017

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified May 2017

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
Active, not recruiting - verified May 2017

Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients

Conditions:   Obesity;   Diabetes
Interventions:   Procedure: Gastric By-Pass;   Drug: optimized medical management
Sponsor:   University Hospital, Lille
Recruiting - verified May 2017

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Completed - verified January 27, 2016

The Effects of Bethanechol on Glucose Homeostasis

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Placebo;   Drug: Bethanechol (25 mg);   Drug: Bethanechol (50 mg);   Drug: Bethanechol (100 mg)
Sponsors:   Washington University School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified May 2017

Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Treatment
Sponsor:   GlaxoSmithKline
Completed - verified May 2017

The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis

Conditions:   Adult Growth Hormone Deficiency;   Hypothalamic-pituitary Disorders
Interventions:   Procedure: Glucagon stimulation test and insulin tolerance test;   Procedure: glucagon stimulation test and insulin tolerance test
Sponsors:   The Cleveland Clinic;   Massachusetts General Hospital;   Allegheny Endocrinology Associates;   Oregon Health and Science University
Completed - verified May 2017

Walking Exercise and Nutrition to Reduce Diabetes Risk for You (WENDY)

Conditions:   Diabetes;   Gestational Diabetes Mellitus
Intervention:   Behavioral: Walking group
Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Mater Mothers Hospital-Australia
Completed - verified May 2017

Healthy Bodies, Healthy Kids

Conditions:   Child Mental Disorders;   Obesity;   Metabolic Syndrome
Interventions:   Behavioral: Behavioral Weight Loss;   Behavioral: Diet and Exercise Education
Sponsors:   Washington University School of Medicine;   National Institute of Mental Health (NIMH)
Completed - verified May 2017

Study of Oral Anthocyanins on Insulin Resistance

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: Mirtoselect
Sponsor:   University of Aberdeen
Recruiting - verified December 2016

Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

Condition:   Type 2 Diabetes
Interventions:   Drug: ACEI or ARB;   Drug: Lisinopril
Sponsor:   University of Virginia
Terminated - verified May 2017

Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus

Conditions:   Obesity;   Bariatric Surgery;   Morbid Obesity;   Diabetes Mellitus Type 2;   Diet Therapy
Interventions:   Procedure: Roux-en-Y Gastric Bypass;   Behavioral: Caloric Restriction
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 3, 2017

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Abnormal Glucose Metabolism;   Type 2 Diabetes
Intervention:   Behavioral: Assignment of a Lay Patient Partner
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 14, 2016

Prevention of Cystic Fibrosis Diabetes

Conditions:   Cystic Fibrosis;   Prediabetes
Intervention:   Drug: Sitagliptin
Sponsor:   Emory University
Terminated - verified May 2017

Pedometers for Gestational Diabetes

Condition:   Gestational Diabetes
Intervention:   Behavioral: Stepping Up to Health
Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified May 2017

Study of the Durability of Glycemic Control With Nateglinide

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Nateglinide;   Drug: Glimepiride
Sponsors:   Ajou University School of Medicine;   Korea University Guro Hospital;   Hanyang University;   Inha University Hospital;   Kyunghee University Medical Center;   Myongji Hospital;   Bundang CHA Hospital;   Wonju Severance Christian Hospital;   Hallym University Medical Center
Completed - verified May 2017

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Conditions:   Diabetes;   Obesity;   Healthy Volunteers
Interventions:   Dietary Supplement: Vitamin E;   Dietary Supplement: Vitamin C
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 7, 2016

Improving the Care of Diabetic Patients: A Randomized Trial of a Family Physician Office-Based Chronic Disease Care Model for Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: multidisciplinary approach;   Other: multifactorial approach - for enhanced care group;   Other: reflects current patterns of care
Sponsors:   University of Alberta;   Alberta Heritage Foundation for Medical Research
Terminated - verified April 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified May 2017

Vascular Risk Progression in Normal and Diabetic Control Subjects.

Conditions:   Diabetes;   Inflammation
Intervention:  
Sponsor:   University of Nebraska
Active, not recruiting - verified May 2017

Predicting Insulin Resistance in American Indian Youth

Conditions:   Insulin Resistance;   Stress, Psychological
Intervention:  
Sponsors:   University of Nebraska;   Indian Health Service (IHS)
Active, not recruiting - verified May 2017

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Vildagliptin;   Drug: Metformin;   Drug: Vildagliptin + Metformin
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: vildagliptin
Sponsor:   Novartis
Completed - verified May 2017

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: vildagliptin;   Drug: Gliclazide;   Drug: Metformin
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: vildagliptin
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: vildagliptin
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Condition:   Diabetic Nephropathy
Intervention:   Drug: aliskiren
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017

A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

Condition:   Foot Ulcer
Intervention:   Drug: rhuMAb VEGF (telbermin)
Sponsor:   Genentech, Inc.
Completed - verified May 2017